抗血管生成药物在非小细胞肺癌中的应用及研究进展(4)
[6]Dowlati A，Gray R，Sandler AB，et al.Cell adhesion molecules， vascular endothelial growth factor， and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study[J].Clin Cancer Res，2008，14(5)：1407-1412.
[7]Dahlberg SE，Sandler AB，Brahmer JR，et al.Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599[J].J Clin Oncol，2010，28(6)：949-954.
, 百拇医药
[8]Wakelee HA，Dahlberg SE，Keller SM，et al.Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505)：an open-label， multicentre， randomised， phase 3 trial[J].Lancet Oncol，2017，18(12)：1610-1623.
[9]Wozniak AJ，Moon J，Thomas CR Jr，et al.A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer： SWOG S0533[J].Clin Lung Cancer，2015，16(5)：340-347.
, 百拇医药
[10]Rosell R，Dafni U，Felip E，et al.Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF)： an international， multicentre， single-arm， phase 2 trial[J].Lancet Respir Med，2017，5(5)：435-444.
[11]Gridelli C，Rossi A，Ciardiello F，et al.BEVERLY： Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer[J].Clin Lung Cancer，2016，17(5)：461-465.
, 百拇医药
[12]Spratlin JL，Cohen RB，Eadens M，et al.Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B)， a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2[J].J Clin Oncol，2010，28(5)：780-787.
[13]Garon EB，Ciuleanu TE，Arrieta O，et al.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL)： a multicentre， double-blind， randomised phase 3 trial[J].Lancet，2014，384(9944)：665-673.
[14]Doebele RC，Spigel D，Tehfe M，et al.Phase 2， randomized， open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous， advanced/metastatic non-small cell lung cancer[J].Cancer，2015，121(6)：883-892., 百拇医药(杨珑静 马洪波 张献全)
[7]Dahlberg SE，Sandler AB，Brahmer JR，et al.Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599[J].J Clin Oncol，2010，28(6)：949-954.
, 百拇医药
[8]Wakelee HA，Dahlberg SE，Keller SM，et al.Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505)：an open-label， multicentre， randomised， phase 3 trial[J].Lancet Oncol，2017，18(12)：1610-1623.
[9]Wozniak AJ，Moon J，Thomas CR Jr，et al.A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer： SWOG S0533[J].Clin Lung Cancer，2015，16(5)：340-347.
, 百拇医药
[10]Rosell R，Dafni U，Felip E，et al.Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF)： an international， multicentre， single-arm， phase 2 trial[J].Lancet Respir Med，2017，5(5)：435-444.
[11]Gridelli C，Rossi A，Ciardiello F，et al.BEVERLY： Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer[J].Clin Lung Cancer，2016，17(5)：461-465.
, 百拇医药
[12]Spratlin JL，Cohen RB，Eadens M，et al.Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B)， a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2[J].J Clin Oncol，2010，28(5)：780-787.
[13]Garon EB，Ciuleanu TE，Arrieta O，et al.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL)： a multicentre， double-blind， randomised phase 3 trial[J].Lancet，2014，384(9944)：665-673.
[14]Doebele RC，Spigel D，Tehfe M，et al.Phase 2， randomized， open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous， advanced/metastatic non-small cell lung cancer[J].Cancer，2015，121(6)：883-892., 百拇医药(杨珑静 马洪波 张献全)